Results

Total Results: 1,187 records

Showing results for "weeks".

61. Cer-276-Ocd-Appendix-H (xls file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-276-ocd-appendix-h.xlsx
    January 01, 2023 - ES 95% CI SE P-Value Favors Strength 25721185 Torp 2015 GPA NordLOTS, stage 1 14 weeks (post-treatment … 0.35  -1.79 to 2.49 0.75 NS Neutral (Nonsignificant) 25721185 Torp 2015 GPA NordLOTS, stage 1 14 weeks … 7-11 Strength unclear (Continuous predictors; P<0.05) 25721185 Torp 2015 GPA NordLOTS, stage 1 14 weeks … 0.15 -0.45 to 0.74 0.631 NS Neutral (Nonsignificant) 25721185 Torp 2015 GPA NordLOTS, stage 1 14 weeks … B 0.06 -0.01 to 0.13 0.83 NS Neutral (Nonsignificant) 25721185 Torp 2015 GPA NordLOTS, stage 1 14 weeks

62. Arthritis and Nontraumatic Joint Disease (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/arthritis-horizon-scan-high-impact-1506.pdf
    June 01, 2015 - , and 4 weeks, followed by one subcutaneous (SC) injection (75 mg) every 4 weeks;3 or secukinumab was … and 4 weeks, followed by one SC injection (75 or 150 mg) every 4 weeks. … , followed by one SC injection every 4 weeks. … ,36 or as three loading doses by IV infusion 10 mg/kg, at baseline, 2 weeks, and 4 weeks, followed … , and 4 weeks, followed by one SC injection (75 or 150 mg) every 4 weeks.

63. Cer-250-Cannabis-Tables-E1-E4-2022-Update 0 (xls file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-250-cannabis-tables-e1-e4-2022-update_0.xlsx
    January 01, 2022 - mg per 100 mcl oromucosal spray (Sativex) titrated to max 6 doses with stable dosing for further 3 weeks … , crossover to ibuprofen 400 mg/day for 8 weeks 0.5 mg/day Ibuprofen 400 mg/day for 8 weeks, crossover … , cross over to ibuprofen 400 mg/day for 8 weeks Ibuprofen 400 mg/day for 8 weeks, crossover to nabilone … , cross over to ibuprofen 400 mg/day for 8 weeks Ibuprofen 400 mg/day for 8 weeks, crossover to nabilone … , cross over to ibuprofen 400 mg/day for 8 weeks Ibuprofen 400 mg/day for 8 weeks, crossover to nabilone

64. Cannabis-2022-Update-Surv-Rep-1-App-F1-4 (xls file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/cannabis-2022-update-surv-rep-1-app-F1-4.xlsx
    January 01, 2022 - mg per 100 mcl oromucosal spray (Sativex) titrated to max 6 doses with stable dosing for further 3 weeks … , crossover to ibuprofen 400 mg/day for 8 weeks 0.5 mg/day Ibuprofen 400 mg/day for 8 weeks, crossover … , cross over to ibuprofen 400 mg/day for 8 weeks Ibuprofen 400 mg/day for 8 weeks, crossover to nabilone … , cross over to ibuprofen 400 mg/day for 8 weeks Ibuprofen 400 mg/day for 8 weeks, crossover to nabilone … , cross over to ibuprofen 400 mg/day for 8 weeks Ibuprofen 400 mg/day for 8 weeks, crossover to nabilone

65. Cer-250-Cannabis-2025-Surv-Rep-Update-Table-E5 (xls file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-250-cannabis-2025-surv-rep-update-table-e5.xlsx
    January 01, 2025 - , Median) Pain Duration, Months Psychiatric Comorbidity % N Interventions Dose Treatment Duration (Weeks … duration for use of Strainprint app (tracking app used to obtain data on medicinal cannabis use): 31 weeks … NA CBD: 202.18 (SD 345.23) 12 weeks (3 months) Short A vs. … of CBD mg/day: 20.00 (20.00 to 40.00) Median (IQR) dosage of THC mg/day: 25.00 (10.00 to 115.00) 52 weeks … B Modified pain disability index, weeks 2 to 24 (95% CI −67.78 to -64.01 vs. −45.23 to −41.46), p<0.001

66. Appendix-E-Evidence-Tables-E1-E4 0 (xls file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/Appendix-E-Evidence-Tables-E1-E4_0.xlsx
    May 29, 2025 - mg per 100 mcl oromucosal spray (Sativex) titrated to max 6 doses with stable dosing for further 3 weeks … , crossover to ibuprofen 400 mg/day for 8 weeks 0.5 mg/day Ibuprofen 400 mg/day for 8 weeks, crossover … , cross over to ibuprofen 400 mg/day for 8 weeks Ibuprofen 400 mg/day for 8 weeks, crossover to nabilone … , cross over to ibuprofen 400 mg/day for 8 weeks Ibuprofen 400 mg/day for 8 weeks, crossover to nabilone … , cross over to ibuprofen 400 mg/day for 8 weeks Ibuprofen 400 mg/day for 8 weeks, crossover to nabilone

67. Systematic Review on Treatments for Acute Pain: Surveillance Report 2 (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/main-apps-surv-report-2-acute-pain.pdf
    May 01, 2022 - ; 2 weeks to less than 4 weeks; 4 weeks or longer? … ; 2 weeks to less than 4 weeks; 4 weeks or longer? … ; 2 weeks to less than 4 weeks; 4 weeks or longer? … ; 2 weeks to less than 4 weeks; 4 weeks or longer? … ; 2 weeks to 4 weeks; ≥4 weeks NOTE: There will not be exclusion criteria for duration, unless duration

68. Cervical Ripening in the Outpatient Setting (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/pdf/ocr-protocol-final_1.pdf
    December 18, 2019 - low-risk nulliparous pregnant women (the ARRIVE trial)5 demonstrated that induction of labor at 39 weeks … , 39 to 41 weeks, >41 weeks) • Pregnant women ≥37 weeks undergoing CR in the outpatient setting … , 39 to 41 weeks, >41 weeks) • Pregnant women ≥37 weeks undergoing CR in the outpatient setting … , 39 to 41 weeks, >41 weeks) • Pregnant women ≥37 weeks undergoing CR with a prostaglandin … , 39 to 41 weeks, >41 weeks) Women with contraindications to CR in the outpatient setting:

69. Living Systematic Review on Cannabis and Other Plant-Based Treatments for Chronic Pain: Surveillance Report 3 (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-250-cannabis-surveillance-report-3_0.pdf
    May 01, 2022 - reviewed evidence, in patients with chronic (mainly neuropathic) pain with short-term treatment (4 weeks … Key Question 2: Harms of cannabinoids for chronic pain compared with placebo in the short term (4 weeks … 8 to 12 weeks 4 to 47 weeks 4 and 12 weeks 4 weeks Abbreviations: CBD = cannabidiol; CBDV = cannabidivarin … Eligible observational studies must have assessed a mean duration of treatment of at least 4 weeks, … Withdrawal due to adverse events for comparable THC to CBD ratio versus placebo (short-term, 4 weeks

70. Living Systematic Review on Cannabis and Other Plant-Based Treatments for Chronic Pain: Surveillance Report 2 (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-250-cannabis-apps-a-e-surveillance-report-2-final_0_0.pdf
    March 01, 2022 - Overall, in patients with chronic (mainly neuropathic) pain with short-term treatment (4 weeks to < … Key Question 2: Harms of cannabinoids for chronic pain compared with placebo in the short term (4 weeks … The findings are applicable to short-term treatment (4 weeks to <6 months) in patients with chronic … 8 to 12 weeks 4 to 47 weeks 4 and 12 weeks 4 weeks Abbreviations: CBD = cannabidiol; CBDV = cannabidivarin … Eligible observational studies must have assessed a mean duration of treatment of at least 4 weeks,

71. Psoriatic Arthritis Surveillance Assesment_CER 54_Low (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/arthritis-psoriatric_surveillance.pdf
    March 01, 2013 - A new meta-analysis9 found PsA Response Criteria (PsARC) response at 12-14 weeks was significantly … ACR20 response at 12-16 weeks was greater for both anti-TNFs and other biologics. … ACR70 response at 12-16 weeks was greater with both anti-TNFs and other biologics than with placebo … for at least 28 weeks. 78.2% had at least one adverse event (AE), but only 4.6% had a No safety … PsA Response Criteria (PsARC) response at 12-14 weeks was greater for anti-TNFs than placebo (

72. Executive summary_Comparative Effectiveness Review No. 250_Living Systematic Review on Cannabis and Other Plant-Based Treatments for Chronic Pain: 2024 Update (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-250-cannabis-2024-surv-rep-update-executive-sum.pdf
    January 01, 2024 - In patients with chronic (mainly neuropathic) pain with short-term treatment (4 weeks to <6 months) … We included RCTs and comparative observational studies with a minimum of 4 weeks duration that assessed … 5.3 to 7.3) 6.75 (4.00 to 8.67)e 6.01 (4.67 to 7.4)f 6.28 (6.12 to 6.44) Study Duration 4 to 15 weeks … 4 to 47 weeks 4 to 16 weeks 4 weeks Abbreviations: CBD = cannabidiol; CBDV = cannabidivarin; MS = … Key Question 2: Harms of cannabinoids for chronic pain compared with placebo in the short term (4 weeks

73. Cannabis-2023-Surv-Rep-4-Table-E-5 (xls file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/cannabis-2023-surv-rep-4-table-E-5.xlsx
    January 01, 2023 - , Median) Pain Duration, Months Psychiatric Comorbidity % N Interventions Dose Treatment Duration (Weeks … NA CBD: 202.18 (SD 345.23) 12 weeks (3 months) Short A vs. … to -50.1 vs. -24.9 to -22.2) LS mean difference: −27.84 (95% CI −29.71 to −25.96), p<0.001 PIX from weeks … B Modified pain disability index, weeks 2 to 24 (95% CI −67.78 to -64.01 vs. −45.23 to −41.46), p<0.001 … B MFHW, weeks 2 to 24: (95% CI 46.24 to 50.46 vs. 5.75 to 1.53), p<0.001 MFHW- mental component summary

74. Cannabis-2022-Surv-Rep-4-Table-F5 (xls file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/cannabis-2022-surv-rep-4-table-F5.xlsx
    January 01, 2022 - , Median) Pain Duration, Months Psychiatric Comorbidity % N Interventions Dose Treatment Duration (Weeks … NA CBD: 202.18 (SD 345.23) 12 weeks (3 months) Short A vs. … to -50.1 vs. -24.9 to -22.2) LS mean difference: −27.84 (95% CI −29.71 to −25.96), p<0.001 PIX from weeks … B Modified pain disability index, weeks 2 to 24 (95% CI −67.78 to -64.01 vs. −45.23 to −41.46), p<0.001 … B MFHW, weeks 2 to 24: (95% CI 46.24 to 50.46 vs. 5.75 to 1.53), p<0.001 MFHW- mental component summary

75. Disposition of Comments_Comparative Effectiveness Review No. 265_Radiation Therapy for Metastatic Bone Disease: Effectiveness and Harms (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-265-radiation-bone-disease-disposition-comments.pdf
    August 29, 2023 - pain is assessed (for example in one study data was included that was only at 2 weeks post treatment … For meta-analyses looking at post-RT up to 4 weeks, if studies reported earlier time frames, we used … the data closest to the 4 weeks for pooled data represented in figure 3 comparing SF and MF EBRT. … Upon review of our data in the meta-analysis, 2 studies reported data for less than 4 weeks: Foro … Arnalot 2008 at 3 weeks and the RR was 0.87 (95% CI 0.75 to 1.02).

76. Type-2-Diabetes-Medications-Update Surveillance (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/type-2-diabetes-medications-update_surveillance.pdf
    December 31, 2013 - weeks 0.001). … and to 11.1+/- 9.9% after 12 weeks. … Change in HbA1c Cross-over: 52 weeks of sitagliptin changed HbA1c by −0.9% from baseline, but … Significant weight reductions occurred after switching to liraglutide for 26 weeks: from 92.8 ± 20.6 … Canagliflozin 100 and 300 mg provided reductions from baseline in body weight over 26 weeks, placebo

77. Executive summary_Comparative Effectiveness Review No. 250_Living Systematic Review on Cannabis and Other Plant-Based Treatments for Chronic Pain: 2025 Update (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-250-cannabis-2025-surv-rep-update-executive-sum.pdf
    January 01, 2025 - ratio) products.4-6 In patients with chronic (mainly neuropathic) pain with short-term treatment (4 weeks … 6.4 to 7.30) 6.75 (4.00 to 8.67)e 6.01 (4.67 to 7.40)f 4.77 (2.54 to 6.28) Study Duration 4 to 15 weeks … 4 to 47 weeks 4 to 16 weeks 4 to 12 weeks Abbreviations: CBD = cannabidiol; CBDV = cannabidivarin … 6.35 (6.1 to 6.6) 4.98 (4.58 to 5.31) 4.4 (4.39 to 4.41) 4.32 (4.31 to 4.33) Study Duration, Weeks … Key Question 2: Harms of cannabinoids for chronic pain compared with placebo in the short term (4 weeks

78. Layout 1 (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/gerd-2005_executive.pdf
    January 01, 2005 - (between classes and within class) PPIs were superior to H2RAs in resolution of GERD symptoms at 4 weeks … and healing of esophagitis at 8 weeks. … difference between omeprazole, lansoprazole, pantoprazole, and rabeprazole for relief of symptoms at 8 weeks … difference in the comparison of esomeprazole 20 mg with omeprazole 20 mg in relief of symptoms at 4 weeks … omeprazole 20 mg, there was a significant difference in favor of esomeprazole for relief of symptoms at 4 weeks

79. Cer-250-Cannabis-2024-Surv-Rep-Update-Table-E5 (xls file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-250-cannabis-2024-surv-rep-update-table-e5.xlsx
    January 01, 2024 - , Median) Pain Duration, Months Psychiatric Comorbidity % N Interventions Dose Treatment Duration (Weeks … NA CBD: 202.18 (SD 345.23) 12 weeks (3 months) Short A vs. … to -50.1 vs. -24.9 to -22.2) LS mean difference: −27.84 (95% CI −29.71 to −25.96), p<0.001 PIX from weeks … B Modified pain disability index, weeks 2 to 24 (95% CI −67.78 to -64.01 vs. −45.23 to −41.46), p<0.001 … B MFHW, weeks 2 to 24: (95% CI 46.24 to 50.46 vs. 5.75 to 1.53), p<0.001 MFHW- mental component summary

80. Depression SSRI Surveillance Assessment_CER 62_Low-1 (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/depression-treatment-ssri_surveillance.pdf
    January 01, 2013 - Outcomes did not differ between the groups at 10 weeks. … Remission rates did not differ among arms at 8 weeks. … Outcomes did not differ from those of placebo group at 4 weeks. … Treatment assignment did not predict outcomes (remission or time to remission) at 48 and 72 weeks … to 55 weeks Overall response rate for all active tx was 52%.